The Lynx Group
Cholangiocarcinoma News

Cholangiocarcinoma

Retrospective exposure-response analysis data support 20 mg once daily as the starting dose for futibatinib, whereas exposure-safety analysis for futibatinib demonstrated a significant relationship between hyperphosphatemia and futibatinib exposure.
Read More

Interim results of the multicenter, dose-escalation/dose-expansion study indicate that RLY-4008 is well-tolerated, demonstrating selective targeting of FGFR2 and the potential to overcome FGFR inhibitor resistance in patients with advanced CCA.
Read More

Primary results from the phase 2 FIDES-01 study indicate that derazantinib yields durable objective responses with a manageable safety profile in patients with intrahepatic CCA who harbor FGFR2 fusions/rearrangements.
Read More

A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Read More

A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
Read More

Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
Read More

A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Read More

A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Read More

Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Read More

Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
Read More

Page 2 of 8


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: